|
|
|
European Biopharmaceutical Review
|
|
The first documented administration of insulin as an intervention
in diabetes was in 1922. A relatively crude extract from bovine pancreas
was injected into a 14-year-old boy in Toronto, and, although the first
injection was not entirely without complications, this intervention
ultimately saved his life. The subsequent impact of this discovery on
the lives of countless patients and our industry has been, to say the
least, transformational. Fast forward a century to 2022, and the
biosimilars of biopharmaceutically manufactured, synthetic insulins will
likely be mainstay therapies for diabetes, as Syneos Health's Rafal
Kokolus, Dr Doug Niven, and Rohit Sood discuss how the illness joins the
list of conditions for which all stakeholders are transitioning towards
biosimilar adoption.
If the rapidly expanding and often complex biosimilars universe is
not quite fully in focus for you yet, then articles in the summer 2018
edition of EBR will provide excellent overviews of the state-of-
the-art in defining by sequence (Dr Richard Easton and Dr Andrew Reason
at BioPharmaSpec) and protecting via optimal patent and commercial
strategies for these high-value ‘affordable’ biological therapeutics,
distinct in sequence and synthesis, yet ‘highly similar’ in efficacy and
safety to first generation proprietary forms of which they are
effectively ‘functional generics’ (Boult Wade Tennant’s Jennifer
O’Farrell, and Finnegans’ Sanya Sukduang and Thomas J Sullivan).
The first ever biosimilar drug product approval (by the EMA in
2006) was for a hormone therapy, omnitrope (somatropin), although the
first biosimilar insulin hormone was only approved as recently as 2014.
Antibody biosimilars, ‘adopted’ by the EMA and FDA more recently, have
made much more ‘noise’, arguably because of the premium priced
proprietary market pioneers they can replace. Three articles in this
edition of EBR focus on antibodies as the targeting component of
antibody-drug conjugates (ADCs) in cancer therapy (the team from Aptamer
Group, and Dr Neil Butt from IONTAS). ADCs are an increasingly
important drug class in oncology, evidenced by the fact that, according
to Professor Andreas Pahl from Heidelberg Pharma, more than 70 are now
in clinical trials.
|
Read full article from PDF >>
|
|
 |
|
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
|
 |
News and Press Releases |
 |
Clinerion expands team and moves to new headquarters in Basel
Clinerion is moving to new offices in Basel, Switzerland. Following strong expansion in its business, the company is in the process of growing its global team. In the six months leading up to the start of 2019, the company expects to have added several additional new positions. Staffing is increasing in all areas of the company, from Customer Solutions to Site & Patient Network Development, from Software Development to Data Analytics and Marketing.
More info >> |
|
 |
White Papers |
 |
|
ConsulTech GmbH
ConsulTech GmbH
ConsulTech is a consulting company founded in 1992. Since then, we have
been supporting biotech-nology, pharmaceutical and medical technology
companies as well as research institutions with the entire process of
setting-up and executing proposals for R&D projects. In projects
funded by the European Commission, ConsulTech supports the coordinator
by resuming administrative tasks allow-ing coordinators and partners to
fully concentrate on the scientific and technical success of the
pro-ject. We solve financial and administrative issues, organise
meetings, take care of the timely delivery of milestones and reports and
much more.
More info >> |
|
 |
Industry Events |
 |
Digital Medicine & Medtech Showcase 2019
8-9 January 2019, Parc 55 San Francisco - a Hilton Hotel
The Digital Medicine and Medtech Showcase is the
dedicated home for the digital health and medtech communities during Biotech Showcase™ and one
of the healthcare industry’s biggest weeks. Taking place January 8–9, Digital
Medicine & Medtech Showcase includes two days of networking opportunities,
curated presentations, specialized sessions, one-to-one meetings scheduled by
partneringONE®, and full access to Biotech Showcase.
More info >> |
|
|
